Valacyclovir therapy to reduce recurrent genital herpes in pregnant women

Autor: Richard J. Whitley, Suzanne P. Cliver, Patrick S. Ramsey, Debora F. Kimberlin, William W. Andrews, Robert G. Deeter

Publikováno v: American Journal of Obstetrics and Gynecology. 194:774-781

Objective The purpose of this study was to estimate the efficacy of valacyclovir suppressive therapy in pregnant women with recurrent genital herpes. Study design At 36 weeks' gestation, herpes simplex virus (HSV)-2 seropositive women were randomized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1223e523bdc7d2b55e6fa9f5a2b96c27
https://doi.org/10.1016/j.ajog.2005.11.051

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Autor: Victoria M. Chia, Sejal Badre, Xiaoyan Li, Henry J. Henk, Arash Naeim, Robert G Deeter, Laura Becker

Publikováno v: BMC Cancer
BMC Cancer, Vol 13, Iss 1, p 11 (2013)
Naeim, Arash; Henk, Henry J; Becker, Laura; Chia, Victoria; Badre, Sejal; Li, Xiaoyan; et al.(2013). Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer, 13(1), 11. doi: http://dx.doi.org/10.1186/1471-2407-13-11. Retrieved from: http://www.escholarship.org/uc/item/9jg999qc

Background Myelosuppressive chemotherapy can lead to dose-limiting febrile neutropenia. Prophylactic use of recombinant human G-CSF such as daily filgrastim and once-per-cycle pegfilgrastim may reduce the incidence of febrile neutropenia. This compar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d62542a5be980bcd4e7fc6ca490dd1ef
https://doi.org/10.1186/1471-2407-13-11

Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up

Autor: A Martin, Lerner, Safedin H, Beqaj, Robert G, Deeter, James T, Fitzgerald

Publikováno v: In vivo (Athens, Greece). 21(5)

We hypothesized that subset classification of Epstein-Barr virus (EBV) in chronic fatigue syndrome (CFS) is required. At first, a blinded-random placebo-controlled trial of valacyclovir in EBV CFS subset was performed (Group 1), and this EBV subset w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dada47eb7c600b8a5bdcbf56eb461d14
https://pubmed.ncbi.nlm.nih.gov/18019402

IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome

Autor: A Martin, Lerner, Safedin H, Beqaj, Robert G, Deeter, James T, Fitzgerald

Publikováno v: In vivo (Athens, Greece). 18(2)

A unique subset of patients with chronic fatigue syndrome (CFS) and IgM serum antibodies to cytomegalovirus (HCMV) non-structural gene products p52 and CM2 (UL 44 and UL 57) has been described.Fifty-eight CFS patients and 68 non-CFS matched controls

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dbd7a238b70e6060f91ad317a878377d
https://pubmed.ncbi.nlm.nih.gov/15113035

Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness

Autor: Michael W. Simon, Robert G. Deeter, Douglas N. Fish

Publikováno v: Drugs in RD. 3(6)

Objective: Valaciclovir has in vitro activity against Epstein-Barr virus (EBV) and, because of improved absorption with higher achievable serum concentrations, may be more effective than aciclovir in the treatment of EBV. No studies to date have eval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba7a05cc85f88c2d9856ae888334d07
https://pubmed.ncbi.nlm.nih.gov/12516939